Extremely not long ago, preliminary benefits from a 3rd trial comparing ibrutinib compared to observation ended up introduced.one hundred and five Patients receiving ibrutinib had a longer function-no cost survival, but no General survival benefit, although the final results ended up however immature. What's more, Whilst severe adverse events price